Northwest Biotherapeutics Mourns the Loss of Les Goldman, Senior Vice President and General Counsel

“`html

BETHESDA, Md., Aug. 18, 2025 /PRNewswire/ — Northwest Biotherapeutics (OTCQB:NWBO), a biotech firm making waves with its DCVax® personalized immune therapies for solid tumor cancers, is mourning the loss of Senior Vice President and General Counsel, Les Goldman, who passed away due to a stroke.

Goldman, a key figure at NW Bio, dedicated years to the company, its shareholders, and the patients it serves. The company extended its deepest condolences to the Goldman family, noting that his responsibilities are currently being absorbed by other members of the management team.

About Northwest Biotherapeutics

Northwest Biotherapeutics is laser-focused on personalized immunotherapy, aiming to deliver cancer treatments that outpace current options in both efficacy and safety – without the harsh side effects of traditional chemotherapy. Their DCVax® platform, which utilizes dendritic cell-based vaccines, is at the heart of this effort. The company’s leading program, DCVax®-L, targets glioblastoma (GBM), a particularly aggressive and devastating form of brain cancer. GBM is considered an “orphan disease,” making effective treatments even more critical.

NW Bio has already completed a 331-patient Phase III trial for DCVax-L targeting GBM. The results, presented at scientific meetings and published in JAMA Oncology, are now under review by regulators in the UK, where the company has submitted a Marketing Authorisation Application (MAA) for commercial approval.

Beyond GBM, NW Bio is also developing DCVax®-Direct for inoperable solid tumors. A 40-patient Phase I trial has been completed, and the company is planning to initiate Phase II trials later this year. The company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.

Disclaimer

This release contains forward-looking statements subject to the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to differ materially, including but not limited to: regulatory processes and decisions, the performance of third parties, the perceived safety and efficacy of the Company’s products, the Company’s ability to raise additional capital, and other risks detailed in the Company’s filings with the Securities and Exchange Commission (SEC). These factors should be considered in evaluating the forward-looking statements, and readers are cautioned not to place undue reliance on such statements. The Company undertakes no obligation to update any forward-looking statements, except as required by law.

CONTACT

Northwest Biotherapeutics

Dave Innes
804-513-6758
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-the-passing-of-its-senior-vice-president-and-general-counsel-mr-les-goldman-302532441.html